Omnicell, Inc. (NASDAQ: OMCL) Stock Competitors & Peer Comparison

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas SIRO's P/E ratio is 31.88. In terms of profitability, OMCL's ROE is +0.03%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, OMCL is more volatile compared to SIRO. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check SIRO's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while HIMS trades at $31.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas HIMS's P/E ratio is -315.90. In terms of profitability, OMCL's ROE is +0.03%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, OMCL is less volatile compared to HIMS. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check HIMS's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while MMED trades at $19.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas MMED's P/E ratio is -25.29. In terms of profitability, OMCL's ROE is +0.03%, compared to MMED's ROE of -0.14%. Regarding short-term risk, OMCL is less volatile compared to MMED. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check MMED's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while DRTS trades at $13.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas DRTS's P/E ratio is -19.61. In terms of profitability, OMCL's ROE is +0.03%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, OMCL is more volatile compared to DRTS. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check DRTS's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, MLAB has a market cap of 574.4M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while MLAB trades at $102.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas MLAB's P/E ratio is 10.36. In terms of profitability, OMCL's ROE is +0.03%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, OMCL is more volatile compared to MLAB. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check MLAB's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, LAB has a market cap of 313.2M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while LAB trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas LAB's P/E ratio is -11.43. In terms of profitability, OMCL's ROE is +0.03%, compared to LAB's ROE of -0.18%. Regarding short-term risk, OMCL is less volatile compared to LAB. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check LAB's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, STXS has a market cap of 139M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while STXS trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas STXS's P/E ratio is -8.35. In terms of profitability, OMCL's ROE is +0.03%, compared to STXS's ROE of -1.53%. Regarding short-term risk, OMCL is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check STXS's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while FONR trades at $19.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas FONR's P/E ratio is 19.09. In terms of profitability, OMCL's ROE is +0.03%, compared to FONR's ROE of +0.04%. Regarding short-term risk, OMCL is more volatile compared to FONR. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check FONR's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while LNSR trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas LNSR's P/E ratio is 6.16. In terms of profitability, OMCL's ROE is +0.03%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, OMCL is less volatile compared to LNSR. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check LNSR's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas KDLY's P/E ratio is -15.48. In terms of profitability, OMCL's ROE is +0.03%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, OMCL is less volatile compared to KDLY. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check KDLY's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while NEUE trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas NEUE's P/E ratio is -0.38. In terms of profitability, OMCL's ROE is +0.03%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, OMCL is more volatile compared to NEUE. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check NEUE's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while SNWV trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas SNWV's P/E ratio is 17.82. In terms of profitability, OMCL's ROE is +0.03%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, OMCL is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SNWV's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, EKSO has a market cap of 38.6M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while EKSO trades at $15.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas EKSO's P/E ratio is -3.11. In terms of profitability, OMCL's ROE is +0.03%, compared to EKSO's ROE of -1.77%. Regarding short-term risk, OMCL is less volatile compared to EKSO. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check EKSO's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while BEAT trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas BEAT's P/E ratio is -0.94. In terms of profitability, OMCL's ROE is +0.03%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, OMCL is less volatile compared to BEAT. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check BEAT's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while STSSW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas STSSW's P/E ratio is -0.03. In terms of profitability, OMCL's ROE is +0.03%, compared to STSSW's ROE of N/A. Regarding short-term risk, OMCL is more volatile compared to STSSW. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check STSSW's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, SPAN has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while SPAN trades at $29.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas SPAN's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, OMCL is less volatile compared to SPAN. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check SPAN's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, EXAC has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while EXAC trades at $49.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, OMCL's ROE is +0.03%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, OMCL is more volatile compared to EXAC. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check EXAC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, ABCO has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while ABCO trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas ABCO's P/E ratio is 0.52. In terms of profitability, OMCL's ROE is +0.03%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, OMCL is more volatile compared to ABCO. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check ABCO's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, SCAI has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while SCAI trades at $55.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas SCAI's P/E ratio is 63.45. In terms of profitability, OMCL's ROE is +0.03%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, OMCL is more volatile compared to SCAI. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check SCAI's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, LDR has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while LDR trades at $67.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas LDR's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to LDR's ROE of +1.17%. Regarding short-term risk, OMCL is more volatile compared to LDR. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check LDR's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, MZOR has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while MZOR trades at $58.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas MZOR's P/E ratio is -70.18. In terms of profitability, OMCL's ROE is +0.03%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, OMCL is more volatile compared to MZOR. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check MZOR's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, MEDC has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas MEDC's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to MEDC's ROE of N/A. Regarding short-term risk, OMCL is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check MEDC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, STJ has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while STJ trades at $80.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas STJ's P/E ratio is 34.69. In terms of profitability, OMCL's ROE is +0.03%, compared to STJ's ROE of +0.21%. Regarding short-term risk, OMCL is more volatile compared to STJ. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check STJ's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, LPNT has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while LPNT trades at $64.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas LPNT's P/E ratio is 67.44. In terms of profitability, OMCL's ROE is +0.03%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, OMCL is more volatile compared to LPNT. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check LPNT's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, CYNO has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while CYNO trades at $66.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas CYNO's P/E ratio is 105.35. In terms of profitability, OMCL's ROE is +0.03%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, OMCL is more volatile compared to CYNO. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check CYNO's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, PMC has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while PMC trades at $29.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas PMC's P/E ratio is 47.95. In terms of profitability, OMCL's ROE is +0.03%, compared to PMC's ROE of +0.04%. Regarding short-term risk, OMCL is more volatile compared to PMC. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check PMC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, ABAX has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while ABAX trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas ABAX's P/E ratio is 70.62. In terms of profitability, OMCL's ROE is +0.03%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, OMCL is more volatile compared to ABAX. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check ABAX's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, EVHC has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while EVHC trades at $45.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas EVHC's P/E ratio is -3.20. In terms of profitability, OMCL's ROE is +0.03%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, OMCL is more volatile compared to EVHC. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check EVHC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, COTV has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while COTV trades at $44.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas COTV's P/E ratio is 26.51. In terms of profitability, OMCL's ROE is +0.03%, compared to COTV's ROE of +0.14%. Regarding short-term risk, OMCL is more volatile compared to COTV. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check COTV's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, AMSG has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while AMSG trades at $67.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas AMSG's P/E ratio is N/A. In terms of profitability, OMCL's ROE is +0.03%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, OMCL is less volatile compared to AMSG. This indicates lower risk in terms of short-term price fluctuations for OMCL.Check AMSG's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, SPNC has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while SPNC trades at $38.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas SPNC's P/E ratio is -24.03. In terms of profitability, OMCL's ROE is +0.03%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, OMCL is more volatile compared to SPNC. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check SPNC's competition here

Omnicell, Inc. (NASDAQ: OMCL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, OMCL stands at 1.7B. In comparison, DSCI has a market cap of 0. Regarding current trading prices, OMCL is priced at $36.81 on the NASDAQ, while DSCI trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

OMCL currently has a P/E ratio of 19.27, whereas DSCI's P/E ratio is -0.02. In terms of profitability, OMCL's ROE is +0.03%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, OMCL is more volatile compared to DSCI. This indicates higher risk in terms of short-term price fluctuations for OMCL.Check DSCI's competition here